Slide 1: 2015 Results
REIG [QJ JOFRE 2015 RESULTS March 2, 2016
Slide 2: Disclosure
DISCLOSURE This presentation contains no confidential material and may include publicly available market information which has not been independently verified by Reig Jofre. This information is given in summary form and does not purport to be complete. Information in this presentation should not be
Slide 3: Contents
CONTENTS 01. SOME BACKGROUND 03. 2015 BALANCE SHEET Main steps in Reig Jofre’s history Assets Business structure Equity and liabilities Specialised development and production sites Markets 04. INTEGRATION PROCESS OF FORTÉ PHARMA WITHIN REIG JOFRE Integration process of Forté Pharma within RJF 02. 20
Slide 4: Some Background
01. SOME BACKGROUND
Slide 5: Main steps in Reig Jofre's history (i)
MAIN STEPS IN REIG JOFRE’S HISTORY (i) 3 GENERATIONS AT BULDING-UP OF A SPECIALISATION IN SPECIALISATION IN THE HEAD OF THE COMPREHENSIVE FREEZE-DRIED ANTIBIOTICS FAMILY BUSINESS PORTFOLIO OF INJECTABLE DERMA AND GENERICS 1989-2004 1929 RESPIRATORY Through the Foundation by PRESCRIPTION 1978-2009 co
Slide 6: Main steps in Reig Jofre's history (ii)
MAIN STEPS IN REIG JOFRE’S HISTORY (ii) MOVING FROM REINVESTING CASHFLOWS REIG JOFRE BECOMES #5 EXPORTS TO DIRECT IN R+D AND OPEN SPANISH PHARMA CO. BY INTERNATIONAL INNOVATION TURNOVER ON THE SPANISH PRESENCE AGREEMENTS STOCK EXCHANGE 2009-… 2013-… December 2014 Reig Jofre merges with 2009 New in
Slide 7: Business structure
BUSINESS STRUCTURE RJF PHARMA RJF CDMO (Manufacture and sale of own developments) (Specialised contract development and manufacturing) TECHNOLOGICAL- THERAPEUTIC- FOOD SUPPLEMENTS AND SPECIALISATION SPECIALISATION CONSUMER HEALTHCARE PRODUCTS PRODUCTS Antibiotics Dermatology Injectable Respiratory/E
Slide 8: Specialised development and production sites
SPECIALISED DEVELOPMENT AND PRODUCTION SITES 8
Slide 9: Markets
MARKETS DIRECT SALES IN 7 MARKETS Spain France Nordic countries Benelux Portugal UK Singapore 155 reps OVER 130 COMMERCIAL PARTNERS IN 58 MARKETS International distributors International licencees 9
Slide 10: 2015 Results
02. 2015 RESULTS
Slide 11: Financial highlights
FINANCIAL HIGHLIGHTS P&L 156.91 M€ turnover (+2.9%), following general growth of 3 RJF Pharma categories and correction of RJF CDMO 17.16 M€ EBITDA (+14.6%) and 10.9% EBITDA margin, from 9.8% in 2014 11.0 M€ profit before taxes (+19.2%) 8.75 net profit (+27.6%) BALANCE SHEET Net financial
Slide 12: Business highlights
BUSINESS HIGHLIGHTS In 2015, approval of 35 marketing authorisations for 10 proprietary Rx PRODUCT REGISTRATIONS / antibiotic/injectable molecules in the following 18 markets: LAUNCHES Australia Hong Kong Philippines Check Republic Hungary Singapore Cyprus Island Spain Denmark Malaysia Sweden Geor
Slide 13: Sales by business areas
SALES BY BUSINESS AREAS +2.9% 2015 RJF PHARMA RJF CDMO turnover: (Own development’s manufacture (Specialised contract development and and sale) manufacturing) 156.9 M€ 79% 21% 124.3 M€ 32.6 M€ TURNOVER BY BUSINESS AREAS 2015 In million euro 140 Direct sales of RJF PHARMA through RJF PHARMA Sales i
Slide 14: Sales by business areas
SALES BY BUSINESS AREAS RJF PHARMA RJF CDMO 79% (Own development’s manufacture and sale) (Specialised contract development and 124.3 M€ manufacturing) TECHNOLOGICAL- THERAPEUTIC- FOOD SUPPLEMENTS AND SPECIALISATION SPECIALISATION CONSUMER HEALTHCARE PRODUCTS PRODUCTS Antibiotics Dermatology Injectab
Slide 15: Sales by geographical areas
SALES BY GEOGRAPHICAL AREAS SALES SPLIT BY GEOGRAPHICAL AREAS IN 2015 156.9 M€ In 2015 Spain grew 4% and Europe progressed by 2%. European markets concentrated 89.9% of sales and had a total growth of 2.7%. Spain 40.8% Rest-of-the-world markets accounted for 10.1% of sales and grew 4.5%. Europe
Slide 16: Top-15 products
TOP-15 PRODUCTS TOP-15 PRODUCTS IN RJF PHARMA 2015 PRODUCT CATEGORY % sales #1 Antibiotic 13% #2 Antibiotic 13% #3 Antibiotic 6% #4 Derma 5% Top-15 products within RJF Pharma accounted for 62.8% of #5 Injectable 4% sales and grew 3.0% in 2015. #6 Food supplement 3% #7 Respiratory/ENT 3% In 2014,
Slide 17: Operating income
OPERATING INCOME Turnover in 2015 stood at 156.9 M€, +2.9% 2014 2015 Evol. versus the previous year. Turnover 152,49 156,91 2,9% Changes in inventories 3,35 -1,61 Gross margin improved from 62% to 63% Procurements -58,61 -57,52 Aprovisionamientos over net sales Gross margin on net sales 97,23 97
Slide 18: Financial result and taxation
FINANCIAL RESULT AND TAXATION 2014 2015 Evol. Operating income 10,03 11,76 17,3% Financial income 0,30 0,21 Financial expenses -0,93 -1,08 Results from the disposal of financial instruments 0,00 -0,30 Results from asset impairment 0,00 0,00 Strong operating growth, followed by stable financial res
Slide 19: 2015 Balance Sheet
03. 2015 BALANCE SHEET
Slide 20: Assets
ASSETS (in euro) 31/12/2015 31/12/2014 On December 31, 2015 RJF had tax credits ASSETS amounting to 15,35 M€ (resulting from 68 M€ Non-current assets tax losses and 4 M€ from deductions). Goodwill 25,165,817 25,405,979 Other intangible assets 32,606,879 32,453,457 Capex of 8.8 M€ Property, plant
Slide 21: Equity and liabilities
EQUITY AND LIABILITIES (in euro) 31/12/2015 31/12/2014 EQUITY AND LIABILITIES Equity Share capital 126,428,441 126,428,441 Reserves -4,533,840 -6,791,795 Treasury shares -4,917,032 -4,901,950 Interim dividend paid during the year 0 0 Profit attributable to the parent company 8,749,701 2,308,394 De
Slide 22: Integration process of Forté Pharma within Reig Jofre
04. INTEGRATION PROCESS OF FORTÉ PHARMA WITHIN REIG JOFRE
Slide 23: Integration process of Forté Pharma within RJF
INTEGRATION PROCESS OF FORTÉ PHARMA WITHIN RJF New strategic plan for Gradual transfer of Forté Strengthening of sales Forté Pharma within RJF: Pharma production to force in Spain and RJF’s sites in 2015-2016 integration into RJF 1. New product development structure and resources in food suppl
Slide 24: Future Overview
05. FUTURE OVERVIEW
Slide 25: Strategic pillars
4 STRATEGIC PILLARS R+D SPECIALISED DEVELOPMENT AND PRODUCTION TECHNOLOGIES OWN BRANDS / FORTÉ PHARMA INTERNATIONALISATION 25
Slide 26: Business areas 2014-2019
BUSINESS AREAS 2014-2019 78% RJF PHARMA RJF CDMO 22% 2014 (Own development’s manufacture and sale) (Specialised contract development and manufacturing) Sales THERAPEUTIC- FOOD SUPPLEMENTS AND SPECIALISED-TECHNOLOGY 152.5 M€ PRODUCTS SPECIALTY PRODUCTS CONSUMER HEALTHCARE EBITDA Antibiotics Dermatolo
Slide 27: Links to complementary info
06. LINKS TO COMPLEMENTARY INFO
Slide 28: Links to complementary information
LINKS TO COMPLEMENTARY INFORMATION Latest news: www.reigjofre.com/en/news Webcast on 2014 results: www.reigjofre.com/en/investors/webcasts Subscription center: www.reigjofre.com/en/subscription-center 28
Slide 29: Investor Relations contact details
Av. de les Flors 08970 Sant Joan Despi Barcelona, Spain T. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com